Quoting Neil Iyengar, Associate Professor at Memorial Sloan Kettering Cancer Center, on X/Twitter:
”New study: Early PIK3CA and Hemoglobin A1c testing is critical to provide time to improve glycemic status before starting alpelisib for metastatic breast cancer. We found Hb A1c and BMI were early risk factors for treatment discontinuation.”
For the article click here.
Source: Neil Iyengar/Twitter
